Back to Search
Start Over
Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas.
- Source :
-
Cancer research [Cancer Res] 2001 Jan 15; Vol. 61 (2), pp. 526-31. - Publication Year :
- 2001
-
Abstract
- Endostatin, a fragment of the COOH-terminal domain of mouse collagen XVIII is a recently demonstrated endogenous inhibitor of tumor angiogenesis and endothelial cell growth. Antiangiogenic therapy with endostatin in animals requires multiple and prolonged administration of the protein. Gene therapy could provide an alternative approach to continuous local delivery of this antiangiogenic factor in vivo. Established MCa-4 murine mammary carcinomas, grown in immunodeficient mice, were treated with intratumoral injection of endostatin plasmid at 7-day intervals. At the time of sacrifice, 14 days after the first injection, endostatin-treated tumor weights were 51% of controls (P < 0.01). Tumor growth inhibition was accompanied by a marked reduction in total vascular density. Specifically, computerized image analysis showed a 18-21% increase in the median distances between tumor cells and both the nearest anatomical (CD31-stained) vessel [48.1 +/- 3.8 versus 38.3 +/- 1.6 microm (P < 0.05)] and the nearest tumor-specific (CD105-stained) vessel [48.5 +/- 1.5 versus 39.8 +/- 1.5 microm (P < 0.01)]. An increased apoptotic index of tumor cells in endostatin-treated tumors [3.2 +/- 0.5% versus 1.9 +/- 0.3% (P < 0.05)] was observed in conjunction with a significant decrease in tumor perfused vessels (DiOC7 staining), and an increase in tumor cell hypoxia (EF5 staining). Hypoxia resulting from endostatin therapy most likely caused a compensatory increase of in situ vascular endothelial growth factor (VEGF) and VEGF receptor mRNA expression. Increased immunoreactivity of endostatin staining in endostatin-treated tumors was also associated with an increased thrombospondin-1 staining [1.12 +/- 0.16 versus 2.44 +/- 0.35]. Our data suggest that intratumoral delivery of the endostatin gene efficiently suppresses murine mammary carcinoma growth and support the potential utility of the endostatin gene for cancer therapy.
- Subjects :
- Animals
Antigens, CD
Collagen Type XVIII
Endoglin
Endostatins
Endothelial Growth Factors genetics
Female
Fluorescent Dyes
Gene Expression Regulation, Neoplastic drug effects
Genetic Therapy
Image Processing, Computer-Assisted
Immunohistochemistry
In Situ Hybridization
Injections, Intralesional
Lymphokines genetics
Mammary Neoplasms, Experimental blood supply
Mammary Neoplasms, Experimental pathology
Mice
Mice, Inbred BALB C
Mice, Nude
Neoplasm Transplantation
Neovascularization, Pathologic genetics
Plasmids genetics
Platelet Endothelial Cell Adhesion Molecule-1 analysis
Proto-Oncogene Proteins c-bcl-2 genetics
RNA, Messenger genetics
RNA, Messenger metabolism
Receptor Protein-Tyrosine Kinases genetics
Receptors, Cell Surface
Receptors, Growth Factor genetics
Receptors, Vascular Endothelial Growth Factor
Treatment Outcome
Tumor Cells, Cultured
Vascular Cell Adhesion Molecule-1 analysis
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
Collagen genetics
Mammary Neoplasms, Experimental therapy
Neovascularization, Pathologic prevention & control
Peptide Fragments genetics
Plasmids administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 0008-5472
- Volume :
- 61
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Cancer research
- Publication Type :
- Academic Journal
- Accession number :
- 11212245